Heinrich Henckel

Article Abstract:

Heinrich Henckel, a lawyer and the CEO of the SWX Swiss Exchange believes and explains that the SWX Swiss Exchange could be as attractive as the London Stock Exchange (LSE). He is convinced about his company's ability to attract biotech listings, even though there is not even one foreign biotech firm that has managed to list on the SWX Swiss Exchange in the initial public offering (IPO).

Financial management, Switzerland, Executive changes & profiles, Security brokers and dealers, Securities & Commodities Services, Securities, Commodity Contracts, and Other Financial Investments and Related Activities, Officials and employees, Finance, Securities industry, Beliefs, opinions and attitudes, Company financing, SWX Swiss Exchange AG, Henckel, Heinrich

---

Can China bring its own pipeline to the market?

Article Abstract:

Reports indicate that even though China's Research and Development (R&D)-based biotechnology industry is in its initial stages, they have more than hundred innovative drugs in the pipeline. It is observed that China can get the drugs approved at a faster rate and at minimum costs but pharmaceutical companies and venture capitalists are hesitant to invest in R&D in China.

China, Product development, Reports, Drug approval

---

IPO floodgates unlikely to open after Ark floatation

Article Abstract:

London based Ark Therapeutics had floated its initial public offering (IPO) on the London Stock Exchange for European biotech firms with the pound sterling 55 investment. Industry experts feel that mergers and acquisitions will offer better opportunities for less mature European biotechnology companies rather than floating an IPO.

Going public (Securities), Initial public offerings, Company public offering, Ark Therapeutics Ltd

Similar abstracts:

• Abstracts: And the winner is... China. Financial sector adds sparkle to economy. Is China the new Japan?
• Abstracts: Genta sued over NDA withdrawal. Maturing biotechs turn to pharma's markets. Redesigner drugs
• Abstracts: Global banks place their bets in China. EU's prospectus Rules fail to roil GDR market. Investment banks cash in on hedge fund boom
• Abstracts: Big pharma wants you. The rise of venture capital and biotechnology in the US and Europe. Term sheet trends in the venture capital market
• Abstracts: EGFR inhibitors square off at ASCO. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.